Sanofi’s Neuro Pipeline Expands to Alzheimer’s With $470M Vigil Neuroscience Acquisition

Sanofi’s Neuro Pipeline Expands to Alzheimer’s With $470M Vigil Neuroscience Acquisition

The Alzheimer’s disease drugs that have reached the market in the past two years are antibodies designed to break up amyloid plaques. Vigil Neuroscience brings to Sanofi a different approach: an oral small molecule designed to activate microglia, immune cells that play a key role in brain health. The post Sanofi’s Neuro Pipeline Expands to Alzheimer’s With $470M Vigil Neuroscience Acquisition appeared first on MedCity News.

DECRYPTAGE - The potential market is considerable. 35 million people worldwide are affected by the disease, and this figure is expected to increase sharply in the coming years.

Sanofi acquisition adds Alzheimer's drug to pipeline

Today's biotech news includes Sanofi adding an Alzheimer's drug to pipeline, ASCO and Google Cloud's cancer guidelines, and more.

Sanofi gains experimental Alzheimer’s drug through Vigil buyout

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing a total deal value of $470 million.

Sanofi makes Alzheimer's play with Vigil takeover

Sanofi bids to add a drug candidate for Alzheimer's disease to its neurology pipeline via the acquisition of US biotech Vigil Neuroscience

Sanofi Acquires Vigil Neuroscience in $470 Million Deal to Bolster Alzheimer’s Drug Pipeline - Channelchek

Key Points:– Sanofi to acquire Vigil Neuroscience for $470 million, expanding its neurology focus.– Deal includes $8 per share and a $2 contingent value right tied to an Alzheimer’s candidate.– The acquisition strengthens Sanofi’s long-term R&D pipeline without impacting 2025 guidance. In a strategic move to deepen its commitment to neuroscience and neurodegenerative disorders, French pharmaceutical giant Sanofi (SASY.PA) announced it will acqui…